Extendicare (TSE:EXE) Hits New 52-Week High – Here’s What Happened

Extendicare Inc. (TSE:EXEGet Free Report) shares reached a new 52-week high on Tuesday . The company traded as high as C$11.35 and last traded at C$11.31, with a volume of 84376 shares trading hands. The stock had previously closed at C$11.12.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on EXE shares. BMO Capital Markets set a C$11.00 price target on Extendicare and gave the company a “market perform” rating in a report on Thursday, January 30th. TD Securities lifted their price target on Extendicare from C$9.50 to C$10.50 and gave the company a “hold” rating in a report on Thursday, November 14th. Finally, Royal Bank of Canada lifted their price target on Extendicare from C$9.50 to C$11.00 and gave the company a “sector perform” rating in a report on Thursday, November 28th.

View Our Latest Research Report on Extendicare

Extendicare Stock Performance

The stock has a market cap of C$946.52 million, a P/E ratio of 14.46 and a beta of 1.26. The company has a fifty day moving average of C$10.44 and a 200 day moving average of C$9.50. The company has a debt-to-equity ratio of 283.02, a current ratio of 0.62 and a quick ratio of 0.98.

Extendicare Announces Dividend

The company also recently announced a monthly dividend, which will be paid on Monday, March 17th. Investors of record on Monday, March 17th will be issued a dividend of $0.04 per share. The ex-dividend date of this dividend is Friday, February 28th. This represents a $0.48 annualized dividend and a yield of 4.23%. Extendicare’s payout ratio is 61.20%.

Extendicare Company Profile

(Get Free Report)

Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.

See Also

Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.